Atossa Therapeutics, Inc. (ATOS)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation

Ask a question about Atossa Therapeutics, Inc. (ATOS)

Company Performance

Current Price

as of Oct 16, 2024

$1.47

P/E Ratio

N/A

Market Cap

$184.86M

Description

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Metrics

Overview

HQSeattle, WA
SectorHealth Technology
IndustryPharmaceuticals: Major
TickerATOS
Price$1.47+2.80%

Trading Information

Market Cap$184.86M
Float99.96%
Average Daily Volume (1m)518,084
Average Daily Volume (3m)577,744
EPS-$0.21

Company

RevenueN/A
Rev Growth (1yr)N/A
Net Income-$6.05M
Gross MarginN/A
EBITDA MarginN/A
EBITDA-$7.10M

EV$69.99M
EV/RevenueN/A
P/EN/A
P/SN/A
P/B2.30

Documents

Factset Street Account

Quantum Leap Healthcare Collaborative initiates landmark Phase 2 RECAST DCIS platform trial to evaluate alternative DCIS treatments ($0.65, -0.02) (2023-10-30T17:04:01Z)

Atossa Therapeutics reports Q3 EPS ($0.05) vs FactSet ($0.07) [3 est, ($0.07)-(0.06)] ($0.64, 0.00) (2023-11-13T14:02:21Z)

Atossa Therapeutics announces full enrollment of Phase 2 Karisma-Endoxifen clinical trial ($0.68, 0.00) (2023-11-20T13:31:45Z)

Earnings Calls

Earnings Report 2023Q2

Earnings Report (2023-08-14)

Factset

Factset Business Description